27m
24/7 Wall St. on MSNHIMS is Out. Is Novo Nordisk or Eli Lilly the Better GLP-1 Buy?The Food & Drug Administration announced last week that the Ozempic and Wegovy shortage for Novo Nordisk's (NYSE:NVO) was ...
Shortages of Ozempic and Wegovy that have been in place for more than two years have been resolved, as supplies of the popular diabetes and obesity treatments continue to improve, federal regulators ...
56m
Hosted on MSNWhat To Expect When IBD 50's No. 2, Hims & Hers, Reports Amid The Semaglutide BattleCompounding pharmacy and IBD 50 newcomer Hims & Hers Health is expected late Monday to report bullish earnings and sales ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results